Spyre reports positive Phase 2 topline data for SPY002 in ulcerative colitis; met primary endpoint

Spyre Therapeutics, Inc.

SPY002 achieved primary endpoint: 10.7-point RHI reduction (p<0.0001) at 12 weeks.
Clinical remission rate 33%, endoscopic improvement rate 42%, modified Mayo Score change -3.7.
Well tolerated; safety profile consistent with TL1A class; no drug-related SAEs.
Two SAEs (UC exacerbation, heart failure) deemed not drug-related; no deaths.
Company on track to report SPY003 Part A data in Q3 2026 and enrolling Part B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.